Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (Nasdaq: BEAM) will present updated BEACON Phase 1/2 results for its investigational sickle cell therapy risto-cel on December 12, 2026. The oral presentation at the American Society of Hematology annual meeting in New Orleans will cover interim efficacy, safety and patient-reported outcomes in adolescents and adults. It has also been selected for ASH’s official press program.
Initial patient-reported outcomes showed early and sustained improvements from baseline in physical function, pain, fatigue, emotional and social well-being, and symptom severity. Beam expects a U.S. Biologics License Application, a request for regulatory approval, as early as year-end 2026. A separate model-based meta-analysis of fetal hemoglobin as a predictor of clinical outcomes and sickling parameters was accepted for publication only in Blood’s online abstract issue.
Beam Therapeutics (Nasdaq: BEAM) reported a third-quarter 2026 net loss of $134.405 million while advancing its base-editing clinical programs. Loss per share was $1.28, versus $1.10 a year earlier; license and collaboration revenue fell to $307,000 from $9.698 million.
BEAM-302 data showed sustained increases in functional alpha-1 antitrypsin and reductions in mutant protein through up to 18 months. Beam expects pivotal-cohort dosing completion in the first half of 2027, a risto-cel sickle cell disease application as early as year-end 2026, and initial BEAM-304 dosing in early 2027. Initial BEAM-301 results showed improved fasting tolerance; enrollment in a higher-dose cohort is underway.
Cash, equivalents and marketable securities totaled $1.0 billion at September 30. Beam expects funding into mid-2029, including an additional $200 million of Sixth Street borrowings subject to borrowing conditions.
Beam Therapeutics (Nasdaq: BEAM) reported initial Phase 1/2 results for BEAM-301, an investigational gene-editing treatment for glycogen storage disease type Ia.
At the August 17, 2026 cutoff, six patients had received a single infusion, with median follow-up of 7.6 months. In the 40 mg cohort, median time to fasting hypoglycemia rose from 2.5 hours at baseline to 15.0 hours at Day 36. Two of three patients reached the 15-hour controlled-fasting maximum; two eliminated daily starch supplementation at their latest assessments. One patient showed no increase in fasting time at the first post-dose assessment.
Four of six patients had serious treatment-emergent adverse events considered treatment-related, including three Grade 3 infusion reactions. No dose-limiting toxicities or Grade 4 or 5 events occurred. Enrollment in the 60 mg cohort is underway, and Beam plans FDA discussions about a potential approval path.
Beam Therapeutics (BEAM) reported initial Phase 1/2 results for BEAM-301 showing improved fasting tolerance in patients with glycogen storage disease type Ia. The therapy targets the R83C mutation. At the June 26, 2026 cutoff, six patients had received one infusion: three each at 20 mg and 40 mg. One 40 mg patient was not yet evaluable for efficacy.
By Day 36, median time to fasting hypoglycemia rose from 2.9 to 4.3 hours at 20 mg; both evaluable 40 mg patients reached ≥15 hours, versus a cohort baseline median of 2.5 hours. Prescribed daily starch intake also declined. All patients had treatment-related adverse events; five serious events resolved within two to 10 days. No dose-limiting toxicities, adverse-event-related discontinuations or deaths were reported. Median follow-up was 313 days at 20 mg and 53 days at 40 mg. Updated results will be presented at ESGCT on October 28, 2026.
Beam Therapeutics (BEAM) reported updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) presented at the 2026 European Respiratory Society Congress.
As of August 17, 2026, 38 patients had received BEAM-302, with efficacy data presented from 29 single-dose patients across lung (Part A) and liver (Part B) cohorts. At the 60 mg dose, mean steady-state total AAT rose from 5.0 µM to 14.4 µM in Part A and from 4.7 µM to 13.5 µM in Part B, exceeding the 11 µM protective threshold, with functional AAT levels increasing dose-dependently and durably. Circulating mutant Z-AAT fell by 84% in both 60 mg cohorts, with corresponding reductions in toxic Z-polymers and dose-proportionate decreases in human neutrophil elastase activity.
Safety remained acceptable, with mostly mild-to-moderate infusion-related reactions in 41% of patients and transient liver enzyme elevations, including one Grade 3 ALT/AST event without bilirubin increase or treatment. Newly produced corrected M-AAT reached 93% of circulating AAT at steady state. Beam has begun dosing a global pivotal cohort using 60 mg and plans to pursue a U.S. accelerated approval pathway based on 12‑month AAT biomarker endpoints.
Beam Therapeutics (Nasdaq: BEAM) announced the appointment of Eric Foster as chief commercial officer, responsible for leading its commercial organization and strategy as multiple precision genetic medicine candidates, including risto-cel, advance toward potential launches, with a targeted potential launch of risto-cel in 2027.
Foster brings more than 25 years of commercial leadership experience in biotechnology and specialty pharmaceuticals. He previously served as CCO at Ardelyx, U.S. general manager at Amgen after its acquisition of Horizon Therapeutics, and led Horizon franchises generating $2.75 billion in net sales revenue, with earlier senior roles at GlaxoSmithKline and Johnson & Johnson.
Beam Therapeutics (Nasdaq: BEAM) announced that its management will take part in fireside chats at three investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, Citi’s Biopharma Back to School Conference on September 9 in New York, and Cantor Fitzgerald Global Healthcare Conference 2026 on September 10 in New York. Live webcasts and 60-day archives will be available in the investor section of Beam’s website.
Beam Therapeutics (Nasdaq: BEAM) reported second quarter 2026 net loss of $122.7 million ($1.18/share) on license and collaboration revenue of $0.5 million, with R&D expenses of $95.1 million and G&A expenses of $31.9 million. Cash, cash equivalents and marketable securities were $1.15 billion at June 30, 2026, and the company expects its cash plus an additional $200 million from its Sixth Street facility to fund operations into mid‑2029.
Operationally, Beam dosed the first patient in the global pivotal cohort of its Phase 1/2 BEAM‑302 trial in AATD, completed dosing of all adult and adolescent patients in the BEACON trial of risto‑cel in SCD, and began clinical start‑up for BEAM‑304 in PKU after U.S. IND clearance. Initial BEAM‑301 data in GSDIa and updated BEACON data are expected in 2026, with a potential risto‑cel BLA submission as early as year‑end 2026.
Beam Therapeutics (Nasdaq: BEAM) will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) in a late-breaking oral session at the European Respiratory Society (ERS) Congress 2026, held September 5–9, 2026 in Barcelona, Spain. BEAM-302 is described by Beam as its lead genetic disease program, a liver-targeting base-editing therapy intended to address both lung and liver manifestations of AATD by restoring AAT levels and function while eliminating toxic Z-AAT.
The late-breaking presentation, titled “First-in-Human in vivo Gene Editing for Severe Alpha-1 Antitrypsin Deficiency (AATD): Initial Data from the Phase 1/2 Study of BEAM-302”, is scheduled in the session “Understanding Treatment Response in Airway Diseases: from Mechanisms to Clinical Biomarkers” on Tuesday, September 8, 2026, from 9:30–10:45 a.m. CEST, and will be delivered by John Hurst, M.D., Ph.D., University College London. Beam also plans an investor conference call and webcast on Tuesday, September 8, 2026, at 7:00 a.m. ET, accessible via the Events section of its website, with a replay available afterward.
Beam Therapeutics (Nasdaq: BEAM) received U.S. FDA clearance of its IND application for BEAM-304, an in vivo base-editing candidate for treating phenylketonuria (PKU).
BEAM-304 uses lipid nanoparticle delivery to correct PAH gene mutations, with preclinical mouse data showing normalization of plasma phenylalanine at clinically relevant doses. A Phase 1/2 trial in PKU patients is planned.